Fenton Mary Kay
Chief Financial Officer
Fenton Mary Kay has filed 4 SEC Form 4 filings (4 transaction rows) across 1 company, with disclosures dating back to 2026. 4 of those filings fall inside the rolling window. Most recent filing: Jul 2, 2026.
On the most recent filing, Fenton Mary Kay is listed as Chief Financial Officer at Cullinan Therapeutics, Inc. Inside the rolling window, Fenton Mary Kay reported no open-market purchases and 1 open-market sale totaling $60K in CGEM.
Companies traded
Other insiders at CGEM
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$60K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Fenton Mary Kay made?
Fenton Mary Kay has filed 4 SEC Form 4 filings (4 transaction rows) across 1 company since 2026.
Which companies does Fenton Mary Kay trade?
Fenton Mary Kay has filed SEC Form 4 disclosures for 1 company, including CGEM.
When was Fenton Mary Kay's most recent SEC Form 4 filing?
Fenton Mary Kay's most recent SEC Form 4 filing on Tracefour is dated Jul 2, 2026.
What is Fenton Mary Kay's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Fenton Mary Kay is listed as Chief Financial Officer.
What is Fenton Mary Kay's total buy and sell value in the current window?
Inside the rolling retention window, Fenton Mary Kay bought $0 and sold $60K based on SEC Form 4 filings.
What was Fenton Mary Kay's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 4,398 CGEM shares on 2026-02-20, worth $60K, per SEC Form 4 filings.